The Fluid Biomarker Core laboratory has studied biomarkers of Alzheimer Disease (AD) for more than 20 years, with a particular interest in preclinical (before symptoms of dementia) and early stage symptomatic AD.

Our laboratory employs a variety of assay platforms (including Enzyme Linked Immunosorbent Assays [ELISA], bead-based immunoassays [Luminex], single-molecule counting systems [SMCxPRO, Simoa), and automated immunoassays [Lumipulse]) to study protein biomarkers in cerebrospinal fluid (CSF) and plasma of participants from a wide variety of research studies. The lab operates according to Good Clinical Practice (GCP) guidelines, utilizing standard operating procedures (SOPs) and defined quality control (QC) metrics. Although considered a research lab, the lab is also involved in the analysis of clinical trial samples for exploratory outcome measures. With the goal of bringing biomarker measures to clinical care, the lab also participates in ongoing, international collaborative efforts to promote biomarker standardization and validation. The laboratory is under the direction of Drs. Anne Fagan, PhD (Core Leader), and Suzanne Schindler, MD, PhD (Associate Core Leader), is funded by many federal NIA/NIH grants and collaborates with philanthropic research organizations and industry partners. Our overarching goal is to better understand the natural course of AD (and other neurodegenerative disorders) pathobiology through the use of fluid biomarkers and evaluate their potential utility for disease diagnosis and prognosis, therapeutic target engagement and clinical trial outcome measures, and eventual therapeutic efficacy once disease-modifying drugs are available to patients suffering from this devastating disease.